Publications Adalimumab for Maintenance of Remission in Crohn’s Disease Citation Townsend CM, Nguyen TM, Cepek J, Abbass M, Parker CE, MacDonald JK, Khanna R, Jairath V, Feagan BG. Adalimumab for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2020 May 16;5(5):CD012877. doi: 10.1002/14651858.CD012877.pub2. PMID: 32413933; PMCID: PMC7386457. Abstract Background: Conventional medications for Crohn’s disease (CD) include anti-inflammatory drugs, immunosuppressants and corticosteroids. If an individual does not respond, or loses response to first-line treatments, then biologic therapies such as tumour necrosis factor-alpha (TNF-α) antagonists such as adalimumab are considered for treating CD. Maintenance of remission of CD is a clinically important goal, as disease relapse can negatively affect quality of life. Tags Adalimumab, Adverse Effects, Anti-Inflammatory Agents, Azathioprine, Crohn's Disease, Drug Therapy, Immunosuppressive Agents, Mercaptopurine, Mesalamine, Placebo, therapeutic use, Treatment Outcome Read More